The divertion strategy of HPV E6/E7 mRNA detection in human papilloma virus persistent infection in cervical diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065856

Enrollment

Unknown

Registered

2022-11-16

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical diseases

Interventions

HPV persistent infection group:None

ASCUS group:None

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old; 2. Sexual life >= 2 years; 3. No recent history of pelvic inflammatory disease; 4. No acute or chronic inflammation in the reproductive tract; 5. Women in non-pregnancy, lactation and pregnancy; 6. Exclude other infectious diseases or other parts of the tumor history; 7. those who have not been vaccinated with HPV vaccine for nearly half a year.

Exclusion criteria

Exclusion criteria: 1. Cervical pathology suggests HSIL or cervical cancer; 2. After total hysterectomy; 3. Information is not complete.

Design outcomes

Primary

Measure	Time frame
Pathology of cervical biopsy;Evaluation of the shunting value of HPV E6/E7 mRNA;	—

Countries

China

Contacts

Public ContactXu Yanli

Department of Obstetrics and Gynecology, Shanghai Jiaotong University Affiliated Sixth People's Hospital

power_xu106@163.com+86 18930174478

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026